Julie A Margenthaler, Facs

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/970709/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Assessing the benefit of adjuvant endocrine therapy in patients following breast-conserving surgery with or without radiation stratified by a 7-gene predictive DCIS biosignature Journal of Clinical Oncology, 2022, 40, 502-502.	1.6	2
2	What matters most: Randomized controlled trial of breast cancer surgery conversation aids across socioeconomic strata. Cancer, 2021, 127, 422-436.	4.1	44
3	Radiation-Induced Brachial Plexopathy in Patients With Breast Cancer Treated With Comprehensive Adjuvant Radiation Therapy. Advances in Radiation Oncology, 2021, 6, 100602.	1.2	9

The Landmark Series: Mastectomy Trials (Skin-Sparing and Nipple-Sparing and Reconstruction Landmark) Tj ETQq0 $\stackrel{0.0}{_{1.5}}$ rgBT / $\stackrel{0}{_{6}}$ verlock 1

5	The Landmark Series: Breast Conservation Trials (including oncoplastic breast surgery). Annals of Surgical Oncology, 2021, 28, 2120-2127.	1.5	27
6	Randomized controlled trial of a breast cancer Survivor Stories intervention for African American women. Social Science and Medicine, 2021, 270, 113663.	3.8	7
7	Surgical Predictive Model for Breast Cancer Patients Assessing Acute Postoperative Complications: The Breast Cancer Surgery Risk Calculator. Annals of Surgical Oncology, 2021, 28, 5121-5131.	1.5	10
8	Implementation and sustainability factors of two early-stage breast cancer conversation aids in diverse practices. Implementation Science, 2021, 16, 51.	6.9	5
9	Impact of consensus guidelines for breastâ€conserving surgery in patients with ductal carcinoma in situ. Cancer Reports, 2021, , e1502.	1.4	3
10	Assessment of Screening Mammography Recommendations. JAMA Internal Medicine, 2021, 181, 1261.	5.1	0
11	Long-Term Outcomes with 3-Dimensional Conformal External Beam Accelerated Partial Breast Irradiation. Practical Radiation Oncology, 2020, 10, e128-e135.	2.1	3
12	The Landmark Series: Axillary Management in Breast Cancer. Annals of Surgical Oncology, 2020, 27, 724-729.	1.5	36
13	Oncologic Safety and Outcomes in Patients Undergoing Nipple-Sparing Mastectomy. Journal of the American College of Surgeons, 2020, 230, 535-541.	0.5	30
14	Indications for readmission following mastectomy for breast cancer: An assessment of patient and operative factors. Breast Journal, 2020, 26, 1966-1972.	1.0	6
15	Surgical Oncologists and the COVID-19 Pandemic: Guiding Cancer Patients Effectively through Turbulence and Change. Annals of Surgical Oncology, 2020, 27, 2600-2613.	1.5	31
16	Single-Institution Phase 1/2 Prospective Clinical Trial of Single-Fraction, High-Gradient Adjuvant Partial-Breast Irradiation for Hormone Sensitive Stage 0-I Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 107, 344-352.	0.8	20
17	A prospective cohort study to analyze the interaction of tumor-to-breast volume in breast conservation therapy versus mastectomy with reconstruction. Breast Cancer Research and Treatment, 2020, 181, 611-621.	2.5	4
18	Robotic Mastectomy—Program Malfunction?. JAMA Surgery, 2020, 155, 461.	4.3	16

#	Article	IF	CITATIONS
19	Repurposing Molecular Imaging and Sensing for Cancer Image–Guided Surgery. Journal of Nuclear Medicine, 2020, 61, 1113-1122.	5.0	35
20	The 2018 Compensation Survey of the American Society of Breast Surgeons. Annals of Surgical Oncology, 2019, 26, 3052-3062.	1.5	9
21	Clinical outcomes and toxicity of proton beam radiation therapy for re-irradiation of locally recurrent breast cancer. Clinical and Translational Radiation Oncology, 2019, 19, 116-122.	1.7	24
22	Value-Based Analysis for Breast Cancer Treatment: We Don't Know What We Don't Know. Annals of Surgical Oncology, 2019, 26, 1167-1169.	1.5	1
23	Treatment response as predictor for brain metastasis in triple negative breast cancer: A scoreâ€based model. Breast Journal, 2019, 25, 363-372.	1.0	6
24	A tale of two operations: re-excision as a quality measure. Gland Surgery, 2019, 8, 593-595.	1.1	5
25	Earlyâ€stage breast cancer and employment participation after 2 years of followâ€up: A comparison with ageâ€matched controls. Cancer, 2018, 124, 2026-2035.	4.1	40
26	What matters most: protocol for a randomized controlled trial of breast cancer surgery encounter decision aids across socioeconomic strata. BMC Public Health, 2018, 18, 241.	2.9	19
27	Long-term outcomes of APBI via multicatheter interstitial HDR brachytherapy: Results of a prospective single-institutional registry. Brachytherapy, 2018, 17, 171-180.	0.5	14
28	Communication as the Key to Breast Conservation. JAMA Surgery, 2018, 153, 36.	4.3	0
29	Adapting the Breast Cancer Surgery Decision Quality Instrument for Lower Socioeconomic Status: Improving Readability, Acceptability, and Relevance. MDM Policy and Practice, 2018, 3, 238146831881183.	0.9	7
30	Bio-inspired imager improves sensitivity in near-infrared fluorescence image-guided surgery. Optica, 2018, 5, 413.	9.3	37
31	Choosing Wisely: Optimizing Routine Workup for the Newly Diagnosed Breast Cancer Patient. Current Breast Cancer Reports, 2018, 10, 62-73.	1.0	2
32	Nipple-Sparing Mastectomy Incisions for Cancer Extirpation Prospective Cohort Trial: Perfusion, Complications, and Patient Outcomes. Plastic and Reconstructive Surgery, 2018, 142, 13-26.	1.4	19
33	Optical See-Through Cancer Vision Goggles Enable Direct Patient Visualization and Real-Time Fluorescence-Guided Oncologic Surgery. Annals of Surgical Oncology, 2017, 24, 1897-1903.	1.5	35
34	NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer. Clinical Cancer Research, 2017, 23, 4055-4065.	7.0	243
35	Cost Analysis of a Surgical Consensus Guideline in Breast-Conserving Surgery. Journal of the American College of Surgeons, 2017, 225, 294-301.	0.5	22
36	Nipple-sparing mastectomies: Clinical outcomes from a single academic institution. Molecular and Clinical Oncology, 2017, 6, 737-742.	1.0	12

#	Article	IF	CITATIONS
37	Perceived social support in African American breast cancer patients: Predictors and effects. Social Science and Medicine, 2017, 192, 134-142.	3.8	63
38	A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i> -Mutant ER-Positive and HER2-Negative Breast Cancer. Clinical Cancer Research, 2017, 23, 6823-6832.	7.0	66
39	Comparison of Wound Complications After Immediate, Delayed, and Secondary Breast Reconstruction Procedures. JAMA Surgery, 2017, 152, e172338.	4.3	58
40	Axillary Ultrasound Before Neoadjuvant Chemotherapy for Breast Cancer: Don't Discount the Benefits Yet!. Annals of Surgical Oncology, 2017, 24, 618-620.	1.5	5
41	Development of a Single Model to Predict Surgical Site Infection and Non-Infectious Wound Complications After Mastectomy with Immediate Reconstruction. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
42	Successful Completion of the Pilot Phase of a Randomized Controlled Trial Comparing Sentinel Lymph Node Biopsy to No Further Axillary Staging in Patients with Clinical T1-T2 NO Breast Cancer and Normal Axillary Ultrasound. Journal of the American College of Surgeons, 2016, 223, 399-407.	0.5	30
43	Development of a Risk Prediction Model to Individualize Risk Factors for Surgical Site Infection After Mastectomy. Annals of Surgical Oncology, 2016, 23, 2471-2479.	1.5	34
44	Effect of Noninfectious Wound Complications after Mastectomy on Subsequent Surgical Procedures and Early Implant Loss. Journal of the American College of Surgeons, 2016, 222, 844-852e1.	0.5	19
45	Breast Conservation Therapy Versus Mastectomy: Shared Decision-Making Strategies and Overcoming Decisional Conflicts in Your Patients. Annals of Surgical Oncology, 2016, 23, 3133-3137.	1.5	20
46	Lymphovascular space invasion and lack of downstaging after neoadjuvant chemotherapy are strong predictors of adverse outcome in young women with locally advanced breast cancer. Cancer Medicine, 2016, 5, 230-238.	2.8	5
47	Incidence of Surgical Site Infection Following Mastectomy With and Without Immediate Reconstruction Using Private Insurer Claims Data. Infection Control and Hospital Epidemiology, 2015, 36, 907-914.	1.8	50
48	Pathological complete response in breast cancer patients following neoadjuvant chemotherapy at a Comprehensive Cancer Center: The natural history of an elusive prognosticator. Molecular and Clinical Oncology, 2015, 3, 775-780.	1.0	4
49	Dual-Modality Photoacoustic and Ultrasound Imaging System for Noninvasive Sentinel Lymph Node Detection in Patients with Breast Cancer. Scientific Reports, 2015, 5, 15748.	3.3	175
50	Binocular Goggle Augmented Imaging and Navigation System provides real-time fluorescence image guidance for tumor resection and sentinel lymph node mapping. Scientific Reports, 2015, 5, 12117.	3.3	46
51	Hormone Replacement Therapy, Likely Neither Angel Nor Demon. PLoS ONE, 2015, 10, e0138556.	2.5	11
52	Staging studies have limited utility for newly diagnosed stage I–II breast cancer. Journal of Surgical Research, 2015, 196, 33-38.	1.6	15
53	Predictors of pathological complete response to neoadjuvant chemotherapy in stage II and III breast cancer: The impact of chemotherapeutic regimen. Molecular and Clinical Oncology, 2015, 3, 1117-1122.	1.0	8
54	Postmastectomy radiation therapy in T3 node-negative breast cancer. Journal of Surgical Research, 2015, 199, 90-96.	1.6	10

Julie A Margenthaler, Facs

#	Article	IF	CITATIONS
55	Economic impact of bleeding complications after mastectomy. Journal of Surgical Research, 2015, 199, 77-83.	1.6	17
56	Venous Thromboembolism after Breast Reconstruction in Patients Undergoing Breast Surgery: An American College of Surgeons NSQIP Analysis. Journal of the American College of Surgeons, 2015, 220, 886-893.	0.5	38
57	Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience. Annals of Surgical Oncology, 2015, 22, 3861-3865.	1.5	6
58	No Surgery for Low-Grade Ductal Carcinoma In Situ?. JAMA Surgery, 2015, 150, 746.	4.3	5
59	Predictors of false negative axillary ultrasound in breast cancer. Journal of Surgical Research, 2015, 198, 351-354.	1.6	10
60	Screening breast magnetic resonance imaging in women with atypia or lobular carcinoma in situ. Journal of Surgical Research, 2015, 193, 519-522.	1.6	30
61	How TNM stage affects surveillance intensity after treatment for breast cancer Journal of Clinical Oncology, 2015, 33, 6547-6547.	1.6	Ο
62	Impact of radiation therapy on survival in patients with triple-negative breast cancer. Oncology Letters, 2014, 7, 548-552.	1.8	45
63	Sentinel lymph node biopsy during prophylactic mastectomy: Is there a role?. Journal of Surgical Oncology, 2014, 109, 747-750.	1.7	10
64	Breast Conservation Surgery and the Definition of Adequate Margins. JAMA Surgery, 2014, 149, 1305.	4.3	1
65	Breast cancer patients' experiences within and outside the safety net. Journal of Surgical Research, 2014, 190, 126-133.	1.6	3
66	Molecular Profiling of Breast Cancer. Surgical Oncology Clinics of North America, 2014, 23, 451-462.	1.5	12
67	Magnetic Resonance Imaging in Patients with Ductal Carcinoma in Situ: Routine, Selective, or not at all?. Annals of Surgical Oncology, 2014, 21, 1510-1511.	1.5	1
68	Intensity of Follow-Up After Breast Cancer Surgery: Low Versus High?. Annals of Surgical Oncology, 2014, 21, 733-737.	1.5	6
69	Predictive Factors and Patterns of Recurrence in Patients with Triple Negative Breast Cancer. Annals of Surgical Oncology, 2014, 21, 2165-2171.	1.5	54
70	Should Ultrasound be a Standard Preoperative Tool in Surgical Planning?. Current Breast Cancer Reports, 2014, 6, 45-50.	1.0	0
71	A Randomized Phase II Presurgical Trial of Transdermal 4-Hydroxytamoxifen Gel versus Oral Tamoxifen in Women with Ductal Carcinoma <i>In Situ</i> of the Breast. Clinical Cancer Research, 2014, 20, 3672-3682.	7.0	68
72	Margin index: a useful tool for the breast surgeon?. Journal of Surgical Research, 2014, 190, 164-169.	1.6	3

#	Article	IF	CITATIONS
73	Patient and Process Factors Associated with Late-Stage Breast Cancer Diagnosis in Safety-Net Patients: A Pilot Prospective Study. Annals of Surgical Oncology, 2013, 20, 723-732.	1.5	20
74	The potential role and mechanisms of distilled water-induced hypotonic shock on malignant cells. Journal of Surgical Research, 2013, 181, 67-68.	1.6	1
75	Surveillance of Patients With Breast Cancer After Curative-Intent Primary Treatment: Current Practice Patterns. Journal of Oncology Practice, 2012, 8, 79-83.	2.5	31
76	Outcomes for Patients who Develop Both Breast and Colorectal Cancer. Annals of Surgical Oncology, 2012, 19, 242-248.	1.5	14
77	ABO Blood Type/Rh Factor and the Incidence and Outcomes for Patients with Triple-Negative Breast Cancer. Annals of Surgical Oncology, 2012, 19, 3159-3164.	1.5	14
78	The Cancer Genome: Translating Sequences into Patient Therapeutics. Journal of Surgical Research, 2012, 174, 245-246.	1.6	0
79	Reconstruction Patterns in a Single Institution Cohort of Women Undergoing Mastectomy for Breast Cancer. Annals of Surgical Oncology, 2012, 19, 3223-3229.	1.5	31
80	Neoadjuvant Chemotherapy Is Associated with Improved Survival Compared with Adjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer Only after Complete Pathologic Response. Annals of Surgical Oncology, 2012, 19, 253-258.	1.5	60
81	Who Benefits from Oncoplastic Surgical Techniques?. Current Breast Cancer Reports, 2012, 4, 132-138.	1.0	0
82	Molecular profiling assays in breast cancer: beyond prime time and into syndication. Oncology, 2012, 26, 362, 364.	0.5	0
83	Ultrasound-Guided Lumpectomy for Palpable Breast Cancers. Annals of Surgical Oncology, 2011, 18, 3198-3203.	1.5	32
84	Endoscopy: Essential or Unnecessary?. Journal of Surgical Research, 2011, 166, 217-218.	1.6	1
85	Invasive Lobular Breast Cancer: Does Grade Matter?. Journal of Surgical Research, 2011, 169, 16-18.	1.6	1
86	Poorer Survival Outcomes for Male Breast Cancer Compared with Female Breast Cancer May Be Attributable to In-Stage Migration. Annals of Surgical Oncology, 2011, 18, 1837-1844.	1.5	81
87	Margin Index Is Not a Reliable Tool for Predicting Residual Disease after Breast-Conserving Surgery for DCIS. Annals of Surgical Oncology, 2011, 18, 3155-3159.	1.5	8
88	Optimizing conservative breast surgery. Journal of Surgical Oncology, 2011, 103, 306-312.	1.7	19
89	Breast cancer in elderly women (≥80 years): variation in standard of care?. Journal of Surgical Oncology, 2011, 103, 201-206.	1.7	33
90	Margin status following partial mastectomy: one size does not fit all!. Oncology, 2011, 25, 899, 903.	0.5	0

#	Article	IF	CITATIONS
91	Margin Index: A New Method for Prediction of Residual Disease After Breast-Conserving Surgery. Annals of Surgical Oncology, 2010, 17, 2696-2701.	1.5	37
92	Use of Breast MRI Surveillance in Women at High Risk for Breast Cancer: A Single-Institutional Experience. Annals of Surgical Oncology, 2010, 17, 263-267.	1.5	115
93	Micrometastatic Disease and Isolated Tumor Cells as a Predictor for Additional Breast Cancer Axillary Metastatic Burden. Annals of Surgical Oncology, 2010, 17, 303-311.	1.5	19
94	Residual Nodal Disease in Biopsy Proven N1/N2 Breast Cancer Following Neoadjuvant Systemic Therapy. World Journal of Surgery, 2010, 34, 256-260.	1.6	3
95	Nonâ€surgical Management Should be Firstâ€ŀine Therapy for Breast Abscess: Reply. World Journal of Surgery, 2010, 34, 2259-2259.	1.6	0
96	The Importance of Complete Pathologic Response After Neoadjuvant Systemic Treatment in Breast Cancer Research and Practice: Reply. World Journal of Surgery, 2010, 34, 1986-1986.	1.6	0
97	Axillary staging prior to or after neoadjuvant systemic therapy? A single institutional experience. Journal of Surgical Oncology, 2010, 102, 404-407.	1.7	3
98	The Impact of Duty Hours on Surgical Resident Education: Are Operative Logs Appropriate Surrogates for Surgical Competence?. Journal of Surgical Research, 2010, 164, 216-217.	1.6	4
99	Surgical resection of the primary tumor in stage IV breast cancer patients: Is a randomized, controlled trial imperative or too costly?. Journal of Surgical Oncology, 2009, 99, 85-86.	1.7	2
100	Patient and tumor characteristics associated with increased mortality in young women (â‰ ¤ 0 years) with breast cancer. Journal of Surgical Oncology, 2009, 100, 248-251.	1.7	131
101	The impact of breast MRI on surgical decisionâ€making: Are patients at risk for mastectomy?. Journal of Surgical Oncology, 2009, 100, 553-558.	1.7	40
102	Predictors of Primary Breast Abscesses and Recurrence. World Journal of Surgery, 2009, 33, 2582-2586.	1.6	69
103	Factors Associated with Lymph Node Assessment in Ductal Carcinoma in situ: Analysis of 1988–2002 Seer Data. Annals of Surgical Oncology, 2008, 15, 2709-2719.	1.5	20
104	Interleukin-12 regulates natural killer cell-dependent Propionibacterium acnes-primed, lipopolysaccharide-induced liver injury. Hepatology Research, 2007, 38, 070809084409004-???.	3.4	1
105	Surgical Removal of the Primary Tumor Increases Overall Survival in Patients With Metastatic Breast Cancer: Analysis of the 1988–2003 SEER Data. Annals of Surgical Oncology, 2007, 14, 2187-2194.	1.5	280
106	Surgical Resection of the Primary Tumor is Associated with Increased Long-Term Survival in Patients with Stage IV Breast Cancer after Controlling for Site of Metastasis. Annals of Surgical Oncology, 2007, 14, 3345-3351.	1.5	191
107	Correlation between core biopsy and excisional biopsy in breast high-risk lesions. American Journal of Surgery, 2006, 192, 534-537.	1.8	88
108	Risk Factors for Adverse Outcomes Following Surgery for Small Bowel Obstruction. Annals of Surgery, 2006, 243, 456-464.	4.2	87

#	Article	IF	CITATIONS
109	Regional oral tolerance in transgenic 2C mice. Surgery, 2005, 138, 141-149.	1.9	0
110	The Immunologic Function of 1B2+ Double Negative (CD4â^'CD8â^') T Cells in the 2C Transgenic Mouse1. Journal of Surgical Research, 2005, 126, 160-166.	1.6	1
111	Outcomes, Risk of Other Malignancies, and Need for Formal Mapping Procedures in Patients With Perianal Bowen's Disease. Diseases of the Colon and Rectum, 2004, 47, 1655-1661.	1.3	40
112	Peripheral tolerance in transgenic mice expressing class I MHC Ld only on cardiac cells. Transplant Immunology, 2004, 12, 133-141.	1.2	1
113	Oral and portal venous tolerance in the interferon-Î ³ knockout (GKO) mouse1. Journal of Surgical Research, 2004, 119, 107-112.	1.6	0
114	Donor-specific renal, but not cardiac, allograft tolerance promotes engraftment of the normally rejected rat skin graft. Transplant International, 2003, 16, 713-720.	1.6	1
115	Effects of endotoxin tolerance on Propionibacterium acnes-primed lipopolysaccharide hepatic injury. Journal of Surgical Research, 2003, 112, 102-110.	1.6	7
116	Mechanism of portal venous tolerant long-term MHC Class I Ld-specific skin graft survival in transgenic 2CF1 mice. Transplant Immunology, 2003, 11, 23-29.	1.2	9
117	Donor-specific antigen transfusion-mediated skin-graft tolerance results from the peripheral deletion of donor-reactive CD8+ T cells. Transplantation, 2003, 75, 2119-2127.	1.0	13
118	Donor-specific renal, but not cardiac, allograft tolerance promotes engraftment of the normally rejected rat skin graft. Transplant International, 2003, 16, 713-720.	1.6	1
119	CD1-Dependent Natural Killer (NK1.1+) T Cells Are Required for Oral and Portal Venous Tolerance Induction. Journal of Surgical Research, 2002, 104, 29-35.	1.6	22